Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd

Bullboard Posts

Comment by 90guppyon May 05, 2020 10:36am

54 Views

Post# 30987516

RE:RE:great news

now the heavy lifting of the research will be done by the hospital R and D. The road for fast track is set.

bligicka wrote: I agree 100%, Really liking how they stated no need for more financing at this time !!!

Vulcan wrote:
partnership with resources as well its stated no need for financing at this time.. means we are not going to be held up over money nor is there dilution.. jmho cheers